Key points are not available for this paper at this time.
Design
Review
May guide early oncology drug decisions; leaves open prospective validation of thresholds before practice change.
Cardiac safety biomarkers are increasingly employed in the preclinical and clinical development of investigational oncology products. Irrespective of overt clinical toxicities, cardiac-related laboratory tests can influence decision making at many levels during the conduct of clinical studies,
No takes yet. Share an insight, caveat, or question.
Fingert et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: